INDUSTRY REACHES INFLECTION POINT

... Records 15% growth with ₹23,524 crore revenues

Serum continues to be the No. 1 biotech company... first biotech company to breach the ₹2,000 crore mark

BioSpectrum-ABLE Biotech Industry Survey 2013

India’s indigenous rotavirus vaccine shows positive results
INDUSTRY INSIGHTS

Biotech industry records `23,524 crore in FY 2012-13

Report on the finding of the 11th annual survey of the biotech industry conducted by BioSpectrum and ABLE.

TOP 100 PHARMA COMPANIES

65 This is the list of the Top 100 pharma companies by revenues and how they fared in 2012-13.

BIOSPECIAL

12 India’s first indigenous rotavirus vaccine is all set to curb the alarming number of diarrhoeal child deaths.
BIOSPECTRUM TOP 20 COMPANIES
BioSpectrum analyzes how the top 20 biotech companies in India performed during 2012-13, their major achievements, and challenges.

#1 Serum Institute of India  p 38
#2 Biocon  p 39
#3 Nuziveedu Seeds  p 40
#4 NovoNordisk  p 41
#5 Syngene International  p 42
#6 Reliance Life Sciences*  p 43
#7 Eli Lilly  p 44
#8 Bharat Serums and Vaccines  p 45
#9 Biological E  p 46
#10 Fortis Clinical Research  p 47
#11 Novozymes South Asia  p 48
#12 Ankur Seeds  p 49
#13 Indian Immunologicals  p 50
#14 GlaxoSimthKline  p 51
#15 Bharat Biotech  p 52
#16 Tulip Group  p 53
#17 Haffkine Bio-Pharmaceutical  p 54
#18 Mahyco  p 55
#19 Advanced Enzymes  p 56
#20 Rasi Seeds  p 57
Rotavac: Taming the terrible infant killer

India’s first indigenous vaccine, Rotavac developed as a result of joint efforts from multiple partners, is all set to curb the alarming number of diarrhoeal child deaths. With the phase III trials showing an impressive data, this affordable vaccine is expected to be in the market by mid 2014.

The seeds of innovation that were sown more than two decades ago have finally grown into fruition. India has achieved success in developing its own highly efficacious and affordable rotavirus vaccine “Rotavac” to tackle the most severe and lethal cause of childhood diarrhoea that kills around 1 lakh Indian children annually. The successful completion of phase III trials of the vaccine is being credited rightly to the intense efforts and commitment shown by the public and private sectors during the 26-year long period. What makes the
After recording growth rates close to the 18 percent during the last five years, the industry slipped further to register 15.08 percent growth. This is the lowest growth that the industry recorded in the past 11 years. The overall bioscience industry, comprising of the biopharmaceuticals, diagnostics, clinical and contract research services, enzymes, bioagri, and bioinformatics, recorded ₹23,524 crore in sales in 2012-13. The BioPharma, clinical trials and contract research sectors account for 82 percent market share today. The BioAgri sector, which has been growing over 20 percent during the last few years, has come crashing with only 5.2 percent growth. The reasons are obvious. There has been complete lull in promotion of transgenic research and regulatory support.

The industry is clearly at an inflection point. Though it missed the $5 billion target, it has not lost hope. It is striving for $100 billion revenues in 2025. Association of Biotechnology Led Enterprises (ABLE) has been making efforts to move towards achieving the number. Dr P M Murali, managing director and CEO, Evolva Biotech and president, ABLE, is optimistic that $100 billion is achievable if the gaps are filled in fast. Ad-hoc policies are not helpful and require more stringent lawmakers say industry stalwarts. A comprehensive regulatory structure in the form of Biotechnology Regulatory Authority of India (BRAI) needs urgent approval by the Parliament to restore the confidence of the industry and kickstart growth.
Corporate Social Responsibility (CSR) is engraved in the DNA of Indian Immunologicals Ltd (IIL). IIL was established in 1983 with an objective of making Foot and Mouth Disease (FMD) vaccine available to farmers at an affordable price. In addition to providing affordable health products, IIL also provides education to rural farmers on health, hygiene, nutrition, productivity and breeding of animals.

In its efforts to enable the government to phase out the usage of the painful and unsafe sheep brain rabies vaccine, IIL, on specific request of the government, set up a human rabies vaccine manufacturing facility in Ooty in 1998 and forayed into manufacturing of human vaccines.

**Raksha Knowledge Summit**

In our endeavor to share knowledge for the benefit of veterinarians, IIL made several initiatives. “Raksha Knowledge Summit” is one such major initiative that has provided a huge national level platform for veterinarians to share views and gain knowledge. Leading veterinarians of the country participate in the summit.

**Zoonosis Day celebration**

IIL’s Zoonosis Day vaccination activities have garnered wide publicity among the pet practitioners over the recent years. Institutions like veterinary hospitals, dispensaries, clinics, cooperatives, and NGOs across the country are coming forward to associate and participate in this rabies awareness program. IIL conducted free anti-rabies vaccination camps across the country on this day.

This year, Zoonosis Day was celebrated in more than 60 places across the country including Ahmedabad, Ajmer, Bangalore, Bhopal, Chennai, Delhi, Jaipur, Ludhiana, Kolkata, Patna, Pune, and Raipur nearly 20,000 animals were freely vaccinated with IIL’s anti-rabies vaccine, Raksharab.